Learning Objectives:

By the end of the program, participants will learn about:

• The differentiation of an Alzheimer’s treatment based on its underlying technology 
• The treatment’s efficacy and safety established from clinical trials and real-world evidence
• Key dosing and administration considerations essential for appropriate use

Speakers:

• Michael McFadden, Chief Executive Officer at Alpha Cognition
• Lauren D’Angelo, Chief Operating Officer at Alpha Cognition
• Kurt Grady, PharmD, Vice President, Medical Affairs at Alpha Cognition

*US-ZUNV-00086 V1